Cargando…
Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study
BACKGROUND: Some parenteral iron therapies have been found to be associated with hypophosphatemia. The mechanism of the decrease in serum phosphate is unknown. The aim of this study is to examine the effect of IV ferric carboxymaltose(FCM) on phosphate metabolism and FGF23 levels in patients with ch...
Autores principales: | Prats, Merche, Font, Ramon, García, Carmen, Cabré, Carmen, Jariod, Manel, Vea, Alberto Martinez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751040/ https://www.ncbi.nlm.nih.gov/pubmed/23902731 http://dx.doi.org/10.1186/1471-2369-14-167 |
Ejemplares similares
-
An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023) -
Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study
por: Portolés-Pérez, Jose, et al.
Publicado: (2019) -
Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014) -
Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020) -
Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)